|
Treatment 1
|
Treatment 2
|
I2 (Weeks 12–16)
|
I2 Sensitivity Analysis (Weeks 12–16)
|
I2 (Weeks 24–28)
|
|
PASI 75
|
|
|
|
|
| Placebo |
Tildrakizumab 100 mg |
0.0% |
0.0% |
0.0% |
| Placebo |
Guselkumab 100 mg |
9.3% |
0.0% |
0.0% |
|
PASI 90
|
|
|
|
|
| Placebo |
Tildrakizumab 100 mg |
0.0% |
0.0% |
0.0% |
| Placebo |
Guselkumab 100 mg |
0.0% |
0.0% |
0.0% |
|
SAE
|
|
|
|
|
| Placebo |
Tildrakizumab 100 mg |
34.1% |
34.1% |
3.9% |
| Placebo |
Guselkumab 100 mg |
0.0% |
0.0% |
NA |
|
Discontinuations
|
|
|
|
|
| Placebo |
Tildrakizumab 100 mg |
0.0% |
0.0% |
84.5% |
| Placebo |
Guselkumab 100 mg |
0.0% |
39.3% |
NA |